Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Individualization of Therapies for Patients With HR-Positive, HER2-Negative Breast Cancer

Featuring Rick Baehner, MD 

 

Rick Baehner, MD, Unviersity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, discussed results from the phase 3 ADAPTcycle trial which used age, recurrence, score (as determined by Oncotype DX), biological markers, and ovarian function suppression to analyze response to short preoperative endocrine therapy in patients with HR-positive, HER2-negative breast cancer.

These results were first presented at the 2023 San Antonio Breast Cancer Symposium.


Source:

Gluz O, Christgen M, Nitz U, et al. Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334). Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract LBO1-05

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement